Sanofi's Biosimilars Deal With JHL Confirms Growing Trend In China
Executive Summary
Sanofi is joining the biosimilars trend to tap into China through a local partnership with Taiwan's JHL Biotech, initially focusing on rituximab, a biosimilar product that has great market potential but strong competition in development by domestic peers.
You may also be interested in...
Three-Decades Tenure But No Loyalty: Genentech Scientist Charged With Biosimilar Trade Secrets Theft
Government indicts former Genentech employees, one of whom admits to secretly working at JHL Biotech and downloading confidential documents. Trade secrets theft case is unusual in two ways: its extraordinary scope and detail and the filing of criminal charges.
Three-Decades Tenure But No Loyalty: Genentech Scientist Charged With Biosimilar Trade Secrets Theft
Government indicts former Genentech employees, one of whom admits to secretly working at JHL Biotech and downloading confidential documents. Trade secrets theft case is unusual in two ways: its extraordinary scope and detail and the filing of criminal charges.
Sanofi’s Keeney On Early-Stage Assets, 'Open Dialogue' With Asian Start-Ups
Dr. Adam Keeney, Global Head, External Innovation and R&D Strategy at Sanofi, outlines in an interview with Scrip the company’s interest in early-stage assets and intent to tap into opportunities in Asia-Pacific. He also discusses the region’s role as a digital hub.